HB-EGF orchestrates the complex signals involved in triple-negative and trastuzumab-resistant breast cancer

Fusanori Yotsumoto, Eiji Oki, Eriko Tokunaga, Yoshihiko Maehara, Masahide Kuroki, Shingo Miyamoto

研究成果: Contribution to journalArticle査読

35 被引用数 (Scopus)

抄録

A number of therapeutic strategies targeting epidermal growth factor receptor (EGFR) have not always led to success in the present state of breast cancer therapy. Notably, there is currently no way to treat trastuzumab- resistant and triple-negative breast cancer (TNBC). Here, we found that heparin-binding epidermal growth factor-like growth factor (HB-EGF), a member of the EGFR ligands, was predominantly expressed in breast cancer and that treatment with crossreacting material 197 (CRM197), a specific inhibitor of HB-EGF, blocked ERK as well as AKT activation via complexes of EGFR and unknown growth factor receptors in TNBC or through complexes of EGFR and human epidermal growth factor receptor-2 in trastuzumab-resistant breast cancer, caused significant cell apoptosis and inhibited tumor growth. Accordingly, we can provide a novel concept that a certain EGFR ligand is recognized as a rational target against breast cancer. In addition, it is plausible that CRM197 could be an effective anticancer agent for molecularly targeted therapies.

本文言語英語
ページ(範囲)2707-2717
ページ数11
ジャーナルInternational Journal of Cancer
127
11
DOI
出版ステータス出版済み - 12 1 2010

All Science Journal Classification (ASJC) codes

  • 腫瘍学
  • 癌研究

フィンガープリント

「HB-EGF orchestrates the complex signals involved in triple-negative and trastuzumab-resistant breast cancer」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル